Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenviro
- PDF / 5,256,101 Bytes
- 240 Pages / 439.43 x 683.15 pts Page_size
- 55 Downloads / 191 Views
Aamir Ahmad Shirish M. Gadgeel Editors
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Advances in Experimental Medicine and Biology Volume 890 Editorial Board: IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel ABEL LAJTHA, N.S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA RODOLFO PAOLETTI, University of Milan, Milan, Italy
More information about this series at http://www.springer.com/series/5584
Aamir Ahmad • Shirish M. Gadgeel Editors
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Editors Aamir Ahmad Karmanos Cancer Institute Wayne State University Detroit, MI, USA
Shirish M. Gadgeel Karmanos Cancer Institute Wayne State University Detroit, MI, USA
ISSN 0065-2598 ISSN 2214-8019 (electronic) Advances in Experimental Medicine and Biology ISBN 978-3-319-24931-5 ISBN 978-3-319-24932-2 (eBook) DOI 10.1007/978-3-319-24932-2 Library of Congress Control Number: 2015960242 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
This is the second part of volume Lung Cancer and Personalized Medicine. Part I of this volume, available as a separate book, discussed lung cancer as a disease, the available therapies and the associated challenges. In this edition, we focus on the upcoming and novel strategies to better understand and target lung cancer. As discussed in the chapters presented here, our understanding of lung cancer and the various factors associated with its onset and progression has vastly improved in last several years. All this information is critical to developing personalized therapies tailored for the benefit of individual patients. A major component of per
Data Loading...
